Life Sciences Patent Network Europe 2019
Veranstaltungsdatum: 21st November 2019
HGF Partner Dr Claire Irvine will be hosting a roundtable on Navigating the CRISPR patent and licensing landscape at Life Sciences Patent Network Europe 2019 on 21st November.
CRISPR gene-editing continues to hit the headlines regularly as a ground-breaking technology with many millions now flowing into companies seeking to exploit the technology in both the therapeutic and agricultural fields. Unfortunately, the IP landscape continues to lack clarity with possibility of divergence between Europe and the US.
Oral proceedings for the University of California have been scheduled at the EPO for early February 2020 with the preliminary non-binding opinion of the opposition division favouring the patentees on coverage extending to CRISPR/Cas9 gene-editing in eukaryotic cells.
Join Dr Claire Irvine’s roundtable session, where she will discuss and update you on:
- The CRISPR IP saga and the interplay between the latest chapter in Europe and the US
- New interference proceedings instigated by the USPTO
- Opposition and appeal proceedings affecting key European patents at the European Patent Office
- The considerations about freedom-to-operate in the absence of resolution of a standard for CRISPR gene-editing for therapy and the growing number of claims outside the main battle lines.